Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Cash from Investing Activities (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Cash from Investing Activities for 15 consecutive years, with $14.3 million as the latest value for Q1 2026.

  • Quarterly Cash from Investing Activities rose 25.75% to $14.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Mar 2026, down 75.14% year-over-year, with the annual reading at $6.1 million for FY2025, 128.32% up from the prior year.
  • Cash from Investing Activities for Q1 2026 was $14.3 million at Achieve Life Sciences, up from $709000.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was $14.3 million in Q1 2026, with the low at -$12.7 million in Q3 2025.
  • Average Cash from Investing Activities over 4 years is $5.7 million, with a median of $9.0 million recorded in 2025.
  • The sharpest move saw Cash from Investing Activities skyrocketed 195383.33% in 2024, then crashed 195.35% in 2025.
  • Achieve Life Sciences' Cash from Investing Activities stood at -$6000.0 in 2023, then skyrocketed by 195383.33% to $11.7 million in 2024, then tumbled by 93.95% to $709000.0 in 2025, then soared by 1913.54% to $14.3 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Cash from Investing Activities are $14.3 million (Q1 2026), $709000.0 (Q4 2025), and -$12.7 million (Q3 2025).